Kidney Disease
New Medication Baxdrostat Shows Promise in Lowering Blood Pressure and Slowing Kidney Disease Progression
The novel medication baxdrostat demonstrated significant reductions in systolic blood pressure and urine albumin levels in patients with chronic kidney disease and uncontrolled hypertension, potentially offering new treatment options for this high-risk population.
Hypertensive Kidney Disease Deaths Surge 48% Over 25 Years, Revealing Persistent Health Disparities
New research shows a nearly 50% increase in U.S. deaths from high blood pressure-related kidney disease since 1999, with Black individuals experiencing death rates over three times higher than other groups, highlighting urgent need for improved screening and management.
SeaStar Medical Expands Acute Kidney Injury Treatment Strategy with Promising Q1 Performance
SeaStar Medical reports significant growth in pediatric acute kidney injury treatment QUELIMMUNE and advances plans to enter the larger adult market, with potential to address a $4.5 billion annual opportunity.
SeaStar Medical Advances Organ-Saving Therapies for Critically Ill Patients
SeaStar Medical is developing innovative medical devices targeting acute kidney injury, leveraging FDA Breakthrough Device Status to potentially transform treatment for critically ill patients across multiple serious conditions.
SeaStar Medical Advances Kidney Injury Treatment with Innovative Pediatric Therapy
SeaStar Medical's QUELIMMUNE therapy offers promising treatment for pediatric acute kidney injury, with FDA approval and early hospital adoption signaling potential breakthrough in a critical healthcare challenge.